| Entries |
| Document | Title | Date |
|---|
| 20080234207 | Pharmaceutical Composition for Preventing and Treating Diabetes or Glucose Control Abnormality Comprising Ginsenosides - The present invention relates to a composition for preventing or treating diabetes or blood glucose control abnormality comprising gisenosides Rg3, Rg5, and Rk1 from natural substances; a use of a mixture comprising gisenosides Rg3, Rg5, and Rk1 for the manufacture of a medicament for preventing or treating diabetes or blood glucose control abnormality; or a method for preventing or treating diabetes or blood glucose control abnormality by administering a therapeutically effective amount of mixture comprising gisenosides Rg3, Rg5, and Rk1 to a subject. The present composition can effectively prevent or treat diabetes, blood glucose control abnormality, and complication thereof. | 09-25-2008 |
| 20080234208 | Medical Composition Containing Ginseng Secondary Glycosides, Its Preparation Method and Application - Medicinal composition containing ginseng secondary glycosides, its preparation method and application. The present composition contains mainly, as active ingredients, the ginsenoside with protopanoxadiol as aglucone (ginsenoside Rg3) and the ginsenoside with protopanoxatriol as aglucone (ginsenoside Rg2 and ginsenoside Rh1). It is prepared from the ginseng genus of plants through extracting, acid hydrolyzing and using macroreticular resin to separate, purify and concentrate. It is useful in the manufacture of medicaments for treating CHD, angina pectoris, myocardial ischemia, hemorrhagic shock, heart failure, and arrhythmia. | 09-25-2008 |
| 20080261899 | AGENT FOR CONTROLLING Bcl-2 EXPRESSION COMPRISING GINSENOSIDE F1 AS AN ACTIVE COMPONENT - The present invention relates to an agent for controlling Bcl-2 expression comprising ginsenoside F1 (20-O-β-D-glucopyranosyl-20(S)-protopanaxatriol) represented by the following formula 1 as an active component. | 10-23-2008 |
| 20080274986 | PHARMACEUTICAL VEHICLE - A pharmaceutical solution is capable of being ejected from a thermal fluid ejection device onto a substrate. The solution includes a vehicle with predetermined properties, and an active pharmaceutical ingredient with a solubility of at least about 30 mg/ml in the vehicle. The vehicle substantially evaporates from the substrate. | 11-06-2008 |
| 20080280838 | Composition Containing Ginsenoside F1 and Egcg for Preventing Skin Damage - The present invention relates to a skin-care composition containing ginsenoside F1 and EGCG. More particularly, the present invention relates to an inhibitor of UV-induced apoptosis in epidermal cells showing an excellent skin-care effect by the synergistic interaction of the said ginsenoside F1 and EGCG even at low concentrations, and to a method for inhibiting apoptosis in epidermal cells. | 11-13-2008 |
| 20080318875 | Core 2 Glcnac-T Inhibitors - The present invention relates to the use of known and novel compounds as inhibitors of UDP-GlcNAc:Galβ1,3GaINAc-R (GlcNAc to GalNAc) β1,6-N-acetylglucosaminyl transferase (core 2 β1,6 N-acetylaminotransferase, core 2 GlcNAc-T-EC 2.4.1.102). Such inhibitors have applications in therapy for diseases associates with raised activity of core 2 GlcNAc-T, in particular inflammatory diseases, atherosclerosis, diabetic cardiomyopathy, cancers—including treatment or prevention of metastasis—or diabetic retinopathy. | 12-25-2008 |
| 20080318876 | Use of Ginsenosides in the Treatment of Aids - The present invention relates to the use of compounds of formula (I) in the treatment of AIDs, | 12-25-2008 |
| 20090005324 | Biologically active extract from dendrobium plant, use thereof and process for preparing the same - A substance having the following formula is provided. | 01-01-2009 |
| 20090012014 | Compound, Composition and a Process Thereof - The present invention provides a novel steroidal glycoside for management of rheumatic and inflammatory disease conditions. In addition, the present invention also provides a process for preparation of steroidal glycoside from plant fenugreek. Further, the invention also provides a pharmaceutical composition of the steroidal glycoside for management of rheumatic disease conditions and its associated disorders. | 01-08-2009 |
| 20090018088 | TREATING CANCER WITH CARDIAC GLYCOSIDES - The invention provides methods to treat cancer with cardiac glycosides. | 01-15-2009 |
| 20090023666 | Modulators of Hypoxia Inducible Factor-1 and Related Uses - The invention features compounds of formulas I or II: and pharmaceutically acceptable salts and prodrugs thereof, as well methods for modulating the effects of local and systemic hypoxic events using the compounds. | 01-22-2009 |
| 20090042813 | Hoodia extract oil compositions comprising medium chain triglycerides - Oil compositions containing | 02-12-2009 |
| 20090054354 | DRUG AND FOOD OR DRINK FOR IMPROVING PANCREATIC FUNCTIONS - Compounds having a cyclolanostane skeleton such as 9,19-cyclolanostan-3-ol and 24-methylene-9,19-cyclolanostan-3-ol are used as an active ingredient of a drug and food or drink for improving pancreatic functions. | 02-26-2009 |
| 20090054355 | Proliferation Inhibitor Of Helicobacter Pylori Including Alpha-N-Acetyl-Glucosaminyl Bond-Containing Monosaccharide Derivatives - The present invention herein provides a proliferation inhibitor of Helicobacter pylori comprising a compound that can simply be mass-produced, can specifically inhibit the proliferation of H. pylori, which has high safety and never generates any resistant bacteria, as well as a diet of a food or beverage, and a pharmaceutical preparation containing the proliferation inhibitor of Helicobacter pylori. The proliferation inhibitor of Helicobacter pylori comprises an alpha-N-acetyl-glucosaminyl bond-containing monosaccharide derivative represented by the following chemical formula (1) | 02-26-2009 |
| 20090062217 | Promoter For The Production Of Hyaluronic Acid Containing Ginsenoside Compound K - There are provided a promoter containing ginsenoside compound K for the production of hyaluronic acid, and more particularly, a new efficacy of 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol (compound K), a chief metabolite of ginseng saponin, to increase the expression of hyaluronic acid synthase gene in human cell and thereby to promote the production of hyaluronic acid, and an anti-aging agent containing the promoter for the production of hyaluronic acid as an effective ingredient. | 03-05-2009 |
| 20090069254 | AGENT FOR INHIBITING VISCERAL FAT ACCUMULATION - To reduce amounts of fat accumulated in abdominal cavity and to prevent or ameliorate visceral fat type obesity considered to be a main factor of metabolic syndrome, there is provided an agent or a food or drink, including as an active ingredient 3-O-β-D-glucopyranosyl-4-methylergost-7-en-3-ol, an organic solvent extract, a hot water extract, a squeezed liquid of a Liliaceae plant or a fraction thereof which contains the compound. | 03-12-2009 |
| 20090075912 | Use of Timosaponin BII in the Preparation Of A Medicament or Product for the Prevention and Treatment of Stroke - The invention disclosed the use of timosaponin BII in the preparation of a medicament or product for the prevention and treatment of stroke. The experiments prove that timosaponin BII can improve the neurological symptoms of cerebral ischemic rat, reduce infarct size, relieve brain water edema, improve hemorheology, reduce inflammatory injury of cerebral ischemia. | 03-19-2009 |
| 20090075913 | GLYCOSIDE HAVING 4-METHYLERGOST-7-EN-3-OL SKELETON AND HYPERGLYCEMIA IMPROVING AGENT - 3-O-β-D-Glucopyranosyl-4-methylergost-7-en-3-ol or a composition containing 0.001% by mass or more of the aforementioned compound, which is an extract of a plant of the family Liliaceae containing the compound or a fraction thereof, is used as an active ingredient of a hyperglycemia improving agent. | 03-19-2009 |
| 20090105163 | Conjugates of Immune Cell Specific Macrolide Compounds with Anti-Inflammatory Compounds for Improved Cellular Targeting of Anti-Inflammatory Therapy - The present invention relates to novel compounds represented by the structure I and pharmaceutical preparations thereof for the treatment of inflammatory diseases in humans and animals. | 04-23-2009 |
| 20090118203 | Administration of agents inducing dopachrome tautomerase (TRP-2) expression for protecting hair follicle melanocytes - Agents inducing the expression of DOPAchrome tautomerase are administered, notably topically applied, to protect and/or regenerate the melanocytes of hair follicles, to promote the cyclic renewal of the follicular pigmentation unit, to prevent and/or limit and/or arrest the development of canities, and to maintain the natural pigmentation of gray or white head hair and/or body hair. | 05-07-2009 |
| 20090181904 | METHOD FOR REGULATING NUTRIENT ABSORPTION WITH GINSENOSIDES - The present application relates to a method of regulating nutrient absorption in a subject in need thereof with an isolated ginsenoside compound. | 07-16-2009 |
| 20090186837 | Anti-neoplastic compositions comprising extracts of black cohosh - A method for treating, preventing or ameliorating breast cancer is provided by administering a synergistic amount of digitoxin and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be paclitaxel. Methods for treating or preventing a neoplasia using a synergistic combination, and compositions of a synergistic combination of a cardiac glycoside and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be a taxane are also provided. The compositions may also be used in a method for modulating Na | 07-23-2009 |
| 20090192097 | Synergistic Herbal Composition from Bacopa Species for Management of Neurodegenerative Disorders and a Process of Preparation Thereof - The present invention relates to a potent synergistic herbal composition [BacoMind®] from the plant species | 07-30-2009 |
| 20090239814 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides - The present invention provides iRNA agents comprising at least one subunit of the formula (I): | 09-24-2009 |
| 20090264376 | Hoodia plant extract with improved flavor - Extracts of | 10-22-2009 |
| 20090264377 | Anti-neoplastic compositions comprising extracts of black cohosh - A method is provided for treating, preventing or ameliorating neoplasia in a subject. This method includes administering to the subject an amount of actein or an amount of an extract of black cohosh that contains a triterpene glycoside, which amount of the actein or black cohosh is effective to treat, prevent or ameliorate the neoplasia, in combination with an amount of a statin which is effective to treat, prevent, or ameliorate the neoplasia. Related methods for treating, preventing or ameliorating breast cancer, or liver cell neoplasia are also provided. In addition, methods for modulating a cholesterol biosynthesis pathway and a stress response pathway in a subject are provided. These methods include administering to a subject a composition comprising an anti-neoplastic synergistic amount of a statin and actein. Compositions for carrying out such methods are also provided. | 10-22-2009 |
| 20090281048 | Method and System for Inducing Anti-aging in Skin - A method of treating the skin and accelerating its natural anti-aging and wound-healing processes by using photorejuvenation at a specified total light flux at a specified range of wavelengths from a hand-held light source in combination with the topical ingredients including extracts. Some extracts may be | 11-12-2009 |
| 20090281049 | New use of ginsenoside compound-k in manufacturing medicaments - Use of ginsenoside Compound-K, which structural formula is the following: | 11-12-2009 |
| 20090312275 | AGENT FOR IMPROVING INSULIN RESISTANCE - To inhibit production of adipocytokines, in particular, adipocytokines that elicit insulin resistance and to prevent onset of pathosis caused by the insulin resistance, or improve the pathosis, the present invention provides an agent or a food or drink which contains 3-O-β-D-glucopyranosyl-4-methylergost-7-en-3-ol, or an organic solvent extract, a hot water extract or a squeezed liquid of a plant of the family Liliaceae or a fraction thereof which contains the compound as an active ingredient. | 12-17-2009 |
| 20090318374 | METHODS OF DIAGNOSING AND TREATING MIGRAINE - The present invention provides methods of diagnosing migraine attacks and determining predisposition of an individual to the development of migraine based on sodium level in the cerebrospinal fluid (CSF) and/or brain extracellular fluid. The invention also provides methods of treating migraine, wherein the individual is selected for treatment based in the individual's sodium level in the CSF and/or brain extracellular fluid. The CSF sodium level may be based on the sodium concentration in the saliva. | 12-24-2009 |
| 20100029577 | Chiral separation, characterization and biological action of optically active isomers of digoxin - Disclosed herein is the method for separation of enantiomers or isomers of digoxin. These isomers are to be used-in the treatment of heart failure without adverse or unneeded cardiac actions in humans. Additionally what is claimed is an isolate with less or no cardiac contractile effect but with AV node slowing such that the composition would be an effective therapy for the control of the ventricular response in atrial fibrillation. Also disclosed are methods for assaying these isomeric compounds present in biological fluids to enable the separation of pharmacologic actions. | 02-04-2010 |
| 20100048494 | Natural Products from Vinca - New and useful compounds | 02-25-2010 |
| 20100048495 | Core 2 GlcNAc-T inhibitors III - A method of treating a subject in need of therapy for a condition involving detrimental activity of the enzyme core 2 GlcNAc-T is provided, comprising administration of a therapeutically effective amount of an inhibitor of core 2 GlcNAc-T of the formula I to a patient in need thereof | 02-25-2010 |
| 20100048496 | Core 2 GlcNAc-T inhibitors - A method of treating a subject in need of therapy for a condition involving detrimental activity of the enzyme core 2 GlcNAc-T is provided, comprising administration of a therapeutically effective amount of an inhibitor of core 2 GlcNAc-T of formula I to a patient in need thereof | 02-25-2010 |
| 20100120704 | Cardiac glycosides to treat cystic fibrosis and other IL-8 dependent disorders - A method of inhibiting the secretion of IL-8 and other pro-inflammatory cytokines from cells secreting elevated levels of these compounds is provided. The method includes contacting the cell with a composition comprising a cardiac glycoside such as oleandrin. The cardiac glycoside can be used to treat cystic fibrosis and other IL-8 dependent disorders by lowering levels of spontaneously secreted IL-8 and other pro-inflammatory cytokines. Oleandrin was found to suppress the secretion of IL-8 from cultured CF lung epithelial cells in the nanomolar concentration range. Structure-activity relationships (SARs) for cardiac glycosides are also elucidated. | 05-13-2010 |
| 20100130436 | CO-ADMINISTRATION OF RANOLAZINE AND CARDIAC GLYCOSIDES - The present invention relates to a method for reducing the toxicity of cardiac glycosides comprising the coadministration of a therapeutically effective amount of cardiac glycoside and a therapeutically effective amount ranolazine. This invention also relates to pharmaceutical formulations that are suitable for such combined administration. | 05-27-2010 |
| 20100137232 | COMPOSITION COMPRISING A DIURETIC AND A CARDIAC GLYCOSIDE FOR THE TREATMENT OF DNA VIRAL INFECTIONS OF THE EYE - DNA viral infections of the eye are treated or prevented by the application of a composition including a diuretic and/or a cardiac glycoside dissolved in a water/ethanol solution wherein the level of the ethanol is adjusted to be acceptable to the eye. | 06-03-2010 |
| 20100179098 | FUROST-5-ENE-3, 22, 26-TRIOL GLYCOSIDE COMPOUND FOR PREVENTING AND TREATMENT CANCER - A pharmaceutical composition for preventing and treating cancer comprising furost-5-ene-3,22,26-triol glycoside, which can be used to prevent and treat cancer by promoting apoptosis. | 07-15-2010 |
| 20100197615 | SYNTHESIS OF COMPOUNDS USEFUL AS MODULATORS OF AMYLOID-BETA PRODUCTION - As described herein, the present invention provides methods for preparing compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease. | 08-05-2010 |
| 20100197616 | Proliferation inhibitor of helicobacter pylori including alpha-n-acetyl-glucosaminyl bond-containing monosaccharide derivatives - A method for inhibiting proliferation of | 08-05-2010 |
| 20100197617 | PROCESS FOR THE PREPARATION OF CARALLUMA EXTRACT AND A FORMULATION PREPARED THEREOF - Processes for the preparation of | 08-05-2010 |
| 20100222286 | RECEPTOR MODULATORS EXHIBITING NEUROPROTECTIVE AND MEMORY ENHANCING ACTIVITIES - The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in preventing and treating central nervous system disorders by inhibiting over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of treating and/or preventing neurodegenerative diseases and neuropathological disorders, methods of providing neuroprotection under stress conditions such as a stroke, methods of enhancing the brain's cognitive functions and methods of treating depression, anxiety and cachexia induced by a chronic disease in mammals and humans. | 09-02-2010 |
| 20100240602 | METHODS AND COMPOSITIONS FOR OPTIMIZING BLOOD AND TISSUE STABILITY OF CAMPTOTHECIN AND OTHER ALBUMIN-BINDING THERAPEUTIC COMPOUNDS - The present invention provides methods and formulations for optimizing the anti-cancer and anti-HIV activities of a camptothecin drug, including camptothecin and its related analogs including 9-aminocamptothecin and 9-nitrocamptothecin. The invention involves methodologies and formulations that limit human serum albumin-mediated reduction of the anti-cancer and anti-HIV effects of the camptothecins, and the methods and formulations provide combination therapies in which binding of the camptothecin agent to human serum albumin can be modulated by the administration of a competing agent such as ibuprofen, clofibrate or clofibric acid that also binds human serum albumin. Reduced camptothecin drug binding to human serum albumin can result in elevated camptothecin free drug levels and thus improve the effectiveness of treatment regimens involving these drugs. Further agents such as methotrexate and AZT can also be used in cancer and HIV-positive patients employing camptothecin drugs. | 09-23-2010 |
| 20100267652 | METHOD OF INHIBITING ABCG2 AND RELATED TREATMENTS - Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2 or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering peliomycin and other compounds described herein. | 10-21-2010 |
| 20100286073 | COMPOUNDS AND METHODS FOR PHARMACEUTICAL USE - The present invention relates to compounds, as well as to compositions, methods and kits comprising such compounds, for use in the treatment or prophylaxis of fibromyalgia, chronic fatigue syndrome, myofascial pain syndrome, Gulf War syndrome and related conditions, wherein the compound is a fatty acid oxidation inhibitor and/or a carbohydrate oxidation activator. | 11-11-2010 |
| 20100286074 | PHARMACEUTICAL USE OF GINSENOSIDE OR MIXTURE THEREOF AND PHARMACEUTICAL COMPOSITION OF GINSENOSIDE AND USE THEREOF - The present invention provides a use of ginsenosides represented by formula I or mixtures thereof for manufacturing a medicament for anti-platelet aggregation, wherein R | 11-11-2010 |
| 20100292176 | ANTITUMOR AGENT - Provided is a sugar-cholestanol compound which can be readily synthesized, and which exhibits a satisfactory antitumor activity. | 11-18-2010 |
| 20100305052 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF - The present application relates to novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridines, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders. | 12-02-2010 |
| 20100323976 | NOVEL ANTI-INFLAMMATORY PRO-DRUGS - The present invention relates to compounds according to formula (I): wherein R | 12-23-2010 |
| 20100331269 | TRITERPENES DERIVATIVES AND USES THEREOF AS ANTITUMOR AGENTS OR ANTI-INFLAMMATORY AGENTS - A compound of formula (I): | 12-30-2010 |
| 20100331270 | ADRENOMEDULLIN PRODUCTION ENHANCER - It is an object of the invention to discover a substance that effectively increases the production of adrenomedullin, as well as to provide an adrenomedullin production-enhancing agent utilizing this substance. The adrenomedullin production-enhancing agent is characterized by inclusion of a ginsenoside, a sanshool, and/or a shogaol as active ingredients. | 12-30-2010 |
| 20110003759 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS - The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I | 01-06-2011 |
| 20110003760 | ABNORMAL PROTEIN REMOVING METHOD - A method for treating symptoms or diseases associated with accumulation of abnormal protein in the body includes administrating to a subject desiring such treatment a composition containing silybin and soybean saponin in an amount effective to reduce or remove abnormal protein produced in the body. | 01-06-2011 |
| 20110015142 | METHOD FOR PREPARING GYNOSTEMMA PENTAPHYLLUM EXTRACT WITH INCREASING DAMULIN A AND DAMULIN B CONTENTS, AND PHARMACEUTICAL COMPOSITIONS OF THE SAME FOR TREATING METABOLIC DISEASE - Disclosed is an AMPK activating material used for improving and treating metabolic syndrome, in which AMPK (AMP-activated protein kinase) is a main enzyme for regulating an energy sensor and lipid/glucose metabolism in the body. The activation of AMPK inhibits the synthesis of fat and cholesterol, and accelerates the reduction of body fat and blood glucose, thereby improving obesity, diabetes, and hyperlipidaemia. The disclosed AMPK activating material contains, as active ingredients having an improving and treating effect on metabolic syndrome, including obesity, diabetes, and hyperlipidaemia, a novel compound 2α,3β,12β-trihydroxydammar-20(22)-E,24-diene-3-O-[β-D-glucopyranosyl-(1→)-β-D-glucopyranoside], named Damulin A, and a novel compound 2α,3β,12β-trihydroxydammara-20,24-diene-3-O-[β-D-glucopyranosyl-(1→)-β-D-glucopyranoside], named Damulin B. Herein, the contents of damulin A and damulin B (as active indicator ingredients for AMPK activation) can be increased by treating a | 01-20-2011 |
| 20110015143 | Use Of One Or More Of Glycyrrhizic Acid For Reducing The Irritating Action Of Surfactants In Cosmetic Compositions - The present invention relates to the use of an agent to combat and reduce the irritating action of primary surfactants in compositions to be applied to the skin for care or cleansing of the face and body, characterized in that said agent is chosen from Cone or more salts of glycyrrhizic acid, such as monoammonium glycyrrhizinate (MAG) and dipotassium glycyrrhizinate (DPG). | 01-20-2011 |
| 20110034403 | USE OF GINSENOSIDE RG1, ITS METABOLITES GINSENOSIDE RH1 AND/OR PPT - The present invention relates to use of an active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt for preparing a medicament and a health care product for improving sexual function of male mammals, and for providing the effect of spermatogenesis. The present invention further relates to a pharmaceutical composition for improving sexual function of male mammals, and/or for providing the effect of spermatogenesis, which comprises at least one active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt, and a pharmaceutically acceptable excipient. | 02-10-2011 |
| 20110039793 | Application of ginsenoside Rb1 in preparing medicaments for treating dilated cardiomyopathy - A method of preparing medicaments for treating dilated cardiomyopathy includes the step of applying ginsenoside Rb1. Long-term treatment of ginsenoside Rb1 can reduce the mortality rate, improve the cardiac function, reduce the dilation of the left ventricular, reduce the hypertrophy of myocytes and the proliferation of collagen, reduce the uneven thickness of myocytes, mitochondrial swelling, break of crista, sarcoplasmic reticulum expansion and destruction of intercalated disc connection, increase the expression of connexin Cx40, E-cadherin and P-cadherin, fibroblast growth factor FGF2, FGF7, FGF8, FGF10, and reduce the expression of integrin Itga8 and Itgbp. | 02-17-2011 |
| 20110046079 | Use of Proton Pump Inhibitors as Drug Delivery Adjuvants - Compositions and methods for drug delivery are disclosed. | 02-24-2011 |
| 20110046080 | Composition for Treating a Skin Disorder - The present invention relates to the use of a plant of the genus, | 02-24-2011 |
| 20110065659 | PROTOPANAXADIOL-TYPE GINSENOSIDE COMPOSITIONS AND USES THEREOF - Provided herein are ginsenoside compositions comprising at least 10% (w/w) of a protopanaxadiol type of ginsenoside suitable for administration to a subject. Also provided are methods using the ginsenoside compositions for reducing acetaldehyde concentrations, preventing or ameliorating a symptom of elevated acetaldehyde concentration, or reducing the risk of diseases or disorders caused by the intake of ethyl alcohol. | 03-17-2011 |
| 20110065660 | Chemosensory Receptor Ligand-Based Therapies - Provided herein are methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions comprising chemosensory receptor ligands. Also provided herein are chemosensory receptor ligand compositions and the preparation thereof for the methods of the present invention. | 03-17-2011 |
| 20110071095 | Compositions and Methods for Increasing Telomerase Activity - The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin ailments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells. | 03-24-2011 |
| 20110136749 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS - As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease. | 06-09-2011 |
| 20110136750 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS - As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease. | 06-09-2011 |
| 20110144043 | Stat modulators - The present invention is directed to methods, kits and compositions for modulating the activity of Stat molecules (e.g., Stat1, Stat3 and Stat5). The compounds of the invention are useful for treating and/or preventing disorders characterized by Stat dysregulation, such as hyperproliferative disorders. Further, the compounds of the present invention are also useful in culturing stem cells and treating ischemic disorders. | 06-16-2011 |
| 20110144044 | Composition and method for increasing post workout recovery - The composition of a dietary supplement is provided for increasing post workout recovery, increasing replenishment and regaining energy following exercise. A method for achieving the same is also provided. The present composition comprises branched chain amino acids, caffeine and a source of carbohydrates including waxy maize. The dietary supplement may further comprise one or more of Ginseng providing ginsenoside saponins, and Fenugreek seeds providing 4-Hydroxyisoleucine. | 06-16-2011 |
| 20110152208 | Use of Compounds Extracted from Momordica Charantia L. in the Manufacture of Medicaments for Prevention and Treatment of Diabetes and Obesity - The present invention disclosed a medical use of cucurbitane triterpenoids represented by the following formula and isolated from | 06-23-2011 |
| 20110152209 | Core 2 GlcNAc-T Inhibitors - The present invention relates to the use of known and novel compounds as inhibitors of UDP-GlcNAc:Galβ1,3GalNAc-R (GlcNAc to GalNAc) β1,6-N-acetylglucosaminyl transferase (core 2 β1,6 N-acetylaminotransferase, core 2 GlcNAc-T-EC 2.4.1.102). Such inhibitors have applications in therapy for diseases associated with raised activity of core 2 GlcNAc-T, in particular inflammatory diseases, atherosclerosis, diabetic cardiomyopathy, cancers—including treatment or prevention of metastasis—or diabetic retinopathy. | 06-23-2011 |
| 20110160152 | EXTRACTS OF AQUILARIA HULLS AND USE THEREOF IN THE TREATMENT OF CANCER - The invention discloses an ethyl acetate layer of methanol extract of | 06-30-2011 |
| 20110160153 | Methods and Compositions for Treating Blood Circulation Disorders - Methods for preparing improved | 06-30-2011 |
| 20110160154 | SUBSTITUTED PIPERAZINES - Disclosed herein are substituted piperazine late Na | 06-30-2011 |
| 20110172172 | Method of Treating Neurological Conditions with Cardiac Glycoside - A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside to a subject. The cardiac glycoside can be present in a dosage form. | 07-14-2011 |
| 20110183928 | 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof - The present application relates to novel 3-cyanoalkyl- and 3-hydroxyalkyl-substituted indole derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of cardiovascular diseases. | 07-28-2011 |
| 20110201564 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF - The present application relates to novel 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindole derivatives, processes for the preparation thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases, and the use thereof for the manufacture of medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders. | 08-18-2011 |
| 20110212909 | Use of Ginsenoside Compound K in the Preparation of a Medicament for the Prevention and Treatment of Atherosclerosis - The invention relates to the fields of Chinese drugs and chemical drugs, specifically, drugs comprising ginsenoside compounds, methods of using ginsenoside compound K shown in Formula 1 for prevention and treatment of atherosclerosis and uses of ginsenoside compound K in the preparation of a medicament for prevention and treatment of atherosclerosis. | 09-01-2011 |
| 20110212910 | ANTIOXIDANT - To provide an antioxidant which is highly safe, inhibits oxidation of a biological component, in particular, a lipid, and is used as a drug, food or drink, a food additive, an external preparation for skin, or the like. The antioxidant contains 3-O-β-D-glucopyranosyl-4-methylergost-7-en-3-ol as an active ingredient. | 09-01-2011 |
| 20110218161 | CYCLOASTRAGENOL MONOGLUCOSIDE, PREPARATION, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF - This invention provides a method for preparing cycloastragenol monoglucoside CMG (cycloastragenol-6-O-β-D-glucoside), comprising the steps of: a. using astragaloside IV or Astragali extracts prepared by a conventional method as raw materials and adding an appropriate solvent thereinto to form a raw material solution; b. adding hydrolase and allowing for hydrolysis at a constant temperature to obtain a hydrolysate; c. separating the hydrolysate with macroporous adsorption resin; and d. obtaining the product by purification and separation. The present invention further provides cycloastragenol-6-O-β-D-glucoside prepared according to the method of this invention as well as its use in the preparation of a medicament for treating cardiovascular diseases and pharmaceutical compositions comprising the same. | 09-08-2011 |
| 20110218162 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS - The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method. | 09-08-2011 |
| 20110251142 | USE OF TRITERPENIC AND ANTHRAQUINONE GLYCOSIDES AS SUBSTANCES EXERTING HYDRAGOGUE ACTIVITY ON MUCOSA OF UPPER RESPIRATORY APPARATUS FOR THE TREATMENT OF THE EFFECTS RESULTING FROM THE UPPER RESPIRATORY TRACT DISEASES - Use of triterpene and anthraquinone glycosides, as substances exerting hydragogue activity on mucosa of upper respiratory apparatus, for the treatment of the effects resulting from the upper respiratory tract diseases. The present invention concerns the use of triterpene and anthraquinone glycosides, as substances exerting hydragogue activity on mucosa of upper respiratory apparatus, for the treatment of the effects resulting from the upper respiratory tract diseases as for example, sinusitis, both acute or chronic, rhinosinusitis, rhinitis. | 10-13-2011 |
| 20110269703 | METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED SAFETY PROFILE OVER CONVENTIONAL WARFARIN THERAPY - A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof. | 11-03-2011 |
| 20110306570 | Na/K-Atpase Expression as an Indicator for the Treatment of Cancer - Methods for regulating the expression of Na/K-ATPase and uses thereof, including uses in the diagnosis/prognosis and treatment of cancer, are disclosed. | 12-15-2011 |
| 20110312903 | FLUORINATION OF ORGANIC COMPOUNDS - Methods for fluorinating organic compounds are described herein. | 12-22-2011 |
| 20110319350 | GLYCOSIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention provides glycoside compounds, methods of preparing such compounds, pharmaceutical compositions comprising such compounds, and a method for the treatment of hyperproliferative diseases using the same. | 12-29-2011 |
| 20110319351 | TREATING CANCER WITH CARDIAC GLYCOSIDES - The invention provides methods to treat cancer with cardiac glycosides. | 12-29-2011 |
| 20110319352 | Compounds That Bind Oxysterol Binding Proteins, and Methods of Use Thereof - The invention relates in part to the discovery that certain CRAMs, such as schweinfurthin A, target OSBPs (a family of oxysterol binding proteins). Because OSBPs have been shown to be integral to atherosclerosis and Alzheimer's disease (AD), one aspect of the invention relates to the use of CRAMs, or a pharmaceutically acceptable salt, biologically active metabolite, solvate, hydrate, prodrug, enantiomer or stereoisomer thereof, in the treatment and/or prevention of atherosclerosis, Alzheimer's disease and related disorders. Another aspect of the invention relates to novel derivatives of CRAMs, or a pharmaceutically acceptable salt, biologically active metabolite, solvate, hydrate, prodrug, enantiomer or stereoisomer thereof, for the treatment and/or prevention of atherosclerosis, Alzheimer's disease and related disorders. Another aspect of the invention relates to the use of an immobilized CRAMs, such as OSW-I, to aid in screening of compounds to identify additional OSBP binders. Other aspects of the invention relate to the use of CRAMs to treat cancer, such as p21-deficient cancers. | 12-29-2011 |
| 20120004188 | USE OF RANOLAZINE FOR TREATING PULMONARY HYPERTENSION - This disclosure relates generally to treating patients having pulmonary hypertension such as pulmonary arterial hypertension (PAH), or symptoms associated therewith, by administering a therapeutically effective amount of ranolazine or a salt or salts thereof to the patient. | 01-05-2012 |
| 20120015894 | AQUEOUS HAIR CLEANSING AGENT - An aqueous hair cleansing agent contains a sulfate-type anionic surfactant having a specific structure, an ether carboxylate-type anionic surfactant having a specific structure, and an organic carboxylic acid or salt thereof, thereby has a pH of 1 to 5 at 25° C. when diluted 20-fold with water. | 01-19-2012 |
| 20120046239 | APPLICATION OF AMERICAN GINSENG TO ENHANCE NEUROCOGNITIVE FUNCTION - Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total genosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness. | 02-23-2012 |
| 20120058961 | Pharmaceutical Composition for Treating Cancers - The preset invention relates to a new approach for treating cancer by using a synergistic combination of a histone deacetylase inhibitor and a furost-5-ene-3,22,26-triol glycoside. A pharmaceutical composition for treating a cancer comprising the synergistic combination and the treatment of a cancer with the synergistic combination are provided. | 03-08-2012 |
| 20120058962 | BUCCAL AND/OR SUBLINGUAL THERAPEUTIC FORMULATION - A buccal and/or sublingual formulation comprising one or more active compounds; and a buccal matrix which releases the active compounds at a predetermined rate for transport across the buccal and/or sublingual membranes, wherein the rate of release of the active compounds is either (A) the same or substantially the same rate at which the active compounds are transported across the buccal and/or sublingual membranes; or (B) a rate which releases the active compounds over an extended period as required by the therapeutic affect or treatment window for those active compounds. | 03-08-2012 |
| 20120071427 | NOVEL ANTIDIABETIC FUROSTANOLIC SAPONIN RICH (FSR) FRACTION FROM FENUGREEK SEEDS - The present invention discloses a novel anti-diabetic composition extracted from fenugreek seeds. The same comprises a furostanolic-saponin-rich fraction (>70%) with approximately 30% protodioscin as one of the bioactive components. Pre-clinical studies in rats indicated significant glucose lowering effect of the fraction (31.5%) as compared to control after two weeks of oral treatment. Clinical studies in human volunteers indicated suitability of a dosage form of 500 mg given once or twice daily as anti-diabetic agent either alone or in combination with standard, synthetic anti-diabetic drugs such as metformin and glipizide in controlling plasma glucose levels. | 03-22-2012 |
| 20120077763 | METHODS FOR TREATING HEART FAILURE BY INHIBITING THE MITOCHONDRIAL SODIUM-CALCIUM EXCHANGER (mNCE) - Methods and compounds for preventing or reducing the toxic side effects of cardiac glycosides by inhibiting the mitochondrial sodium-calcium exchanger (mNCE) are provided. Methods and compositions for preventing or reducing the occurrence of conditions associated with heart failure, including, but not limited to, sudden cardiac death and contractile decompensation, by inhibiting the mNCE also are provided. | 03-29-2012 |
| 20120094944 | NOVEL IMIDAZOPYRIDINE COMPOUND - For the prevention and/or treatment of chymase-mediated diseases such as skin diseases, circulatory diseases, digestive system diseases, respiratory diseases, liver diseases, ocular diseases or the like, a drug is provided having as an active ingredient a compound having extremely strong chymase inhibitory activity, high safety, and high metabolic stability. The compound represented by the formula (I): | 04-19-2012 |
| 20120101052 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS - The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method. | 04-26-2012 |
| 20120122807 | Cardiac Glycoside Analogs in Combination with Emodin for Cancer Therapy - A method and medicine for treating leukemia or other cancer includes administering to a patient diagnosed with leukemia or other cancer a treatment regimen that includes periodic doses of a combination of emodin and digoxin. | 05-17-2012 |
| 20120142620 | CORE 2 GLCNAC-T INHIBITORS - A method of treating a subject in need of therapy for a condition involving detrimental activity of the enzyme core 2 GlcNAc-T is provided, comprising administration of a therapeutically effective amount of an inhibitor of core 2 GlcNAc-T of formula I to a patient in need thereof | 06-07-2012 |
| 20120149656 | WATER SOLUTION OF 20(R) - GINSENOSIDE Rg3 PHARMACEUTICAL COMPOSITION AND PROCESS THEREOF - A preparation of a kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution containing ginsenoside Rg3 0.5˜10 mg/ml: add 0.1-5% of ginsenoside solution to 0.1˜30% of adjuvant A, B{circle around (1)}{circle around (2)}{circle around (5)} at the temperature of 40˜100° C., the ratio of these two is 1:1˜300, add water after the solvent is recycled under reduced pressure; another kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution contains 0.1˜2 mg/ml of 20 (R) of the ginsenoside Rg3, the preparation: add 0.1˜5% of ginsenoside solution to 20˜65% of adjuvant B{circle around (3)}{circle around (4)} at the temperature of 60˜100° C., main material to adjuvant B=1:100˜400, add water after the solvent is recycled under reduced pressure. The above 20 (R) ginsenoside Rg3 composition aqueous solution and the powder after lyophilizaton can be used to prepare injectable, oral administration and external use, and the bioactivity of these preparations is high, and with the actions of anti cancer, efficacy potentiation and toxicity attenuation effects of the combined chemical or radiation therapy of tumor, enhancement of human immune functions, improvement of human memory, anti fatigue, and detumescence, pain relieving. | 06-14-2012 |
| 20120190635 | SELECTIVE OXIDATION OF C-H BONDS OF MODIFIED SUBSTRATES BY P450 MONOOXYGENASE - The present invention provides regio- and stereoselective oxidation of unactivated C—H bonds using an engineered mutant cytochrome P450 monooxygenase and an engineered substrate. | 07-26-2012 |
| 20120196815 | Withanolide Isolated from Physalis longifolia and Analogs and Methods of Use Thereof - The present invention features novel withanolides, as well as analogs and salts thereof, for use in the treatment of proliferative disease, cardiovascular disease, neurodegenerative disease and inflammatory disease. | 08-02-2012 |
| 20120196816 | METHOD FOR ENHANCING NUTRIENT ABSORPTION WITH ASTRAGALOSIDES - The present application relates to a method for enhancing absorption of a nutrient in a subject in need thereof with an effective amount of an isolated astragaloside compound. | 08-02-2012 |
| 20120196817 | METHOD FOR ENHANCING NUTRIENT ABSORPTION WITH ASTRAGALOSIDES - The present application relates to a method for enhancing absorption of a nutrient in a subject in need thereof with an effective amount of an isolated astragaloside compound. | 08-02-2012 |
| 20120202757 | ANTIHYPERTENSIVE COMPOSITION CONTAINING A GINSENOSIDE-ENRICHED FRACTION - The present invention related to an antihypertensive composition containing a fraction enriched with ginsenosides of ginseng. The composition according to the present invention increases the production of nitric oxide through the activation of nitric oxide synthase, and thus exhibits superior antihypertensive effects through the vasodilatory activity. Consequently, the composition of the present invention can be used as a composition for preparing functional health foods for preventing and treating hypertension and various cardiovascular diseases caused by complications of hypertension. | 08-09-2012 |
| 20120202758 | CORE 2GLCNAC-T INHIBITORS - Treatments for conditions involving detrimental activity of the enzyme core 2 GlcNAc-T are provided using compounds of the formula I | 08-09-2012 |
| 20120208776 | ANTI-NEOPLASTIC COMPOSITIONS COMPRISING EXTRACTS OF BLACK COHOSH - A method is provided for treating, preventing or ameliorating neoplasia in a subject. This method includes administering to the subject an amount of actein or an amount of an extract of black cohosh that contains a triterpene glycoside, which amount of the actein or black cohosh is effective to treat, prevent or ameliorate the neoplasia, in combination with an amount of a statin which is effective to treat, prevent, or ameliorate the neoplasia. Related methods for treating, preventing or ameliorating breast cancer, or liver cell neoplasia are also provided. In addition, methods for modulating a cholesterol biosynthesis pathway and a stress response pathway in a subject are provided. These methods include administering to a subject a composition comprising an anti-neoplastic synergistic amount of a statin and actein. Compositions for carrying out such methods are also provided. | 08-16-2012 |
| 20120245110 | VASCULAR LEAKAGE INHIBITOR - The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present disclosure inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, enhances the cortical actin ring structure, and improves the stability of the tight junctions (TJs) between vascular cells, thereby inhibiting vascular leakage. The vascular leakage inhibitor of the present disclosure has the activity of not only reducing vascular permeability but also recovering the integrity of damaged blood vessels. Accordingly, the vascular leakage inhibitor of the present disclosure can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present disclosure is synthesized from commercially available or easily synthesizable cholesterols, it has remarkably superior feasibility of commercial synthesis. | 09-27-2012 |
| 20120258923 | BIOACTIVITY COMPOSITION OF Reevesia formosana - A series cardenolide derivatives including structure of formula I from the root of | 10-11-2012 |
| 20120264704 | SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS - The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing. | 10-18-2012 |
| 20120270816 | METHODS OF DIAGNOSING AND TREATING MIGRAINE - The present invention provides methods of diagnosing migraine attacks and determining predisposition of an individual to the development of migraine based on sodium level in the cerebrospinal fluid (CSF) and/or brain extracellular fluid. The invention also provides methods of treating migraine, wherein the individual is selected for treatment based in the individual's sodium level in the CSF and/or brain extracellular fluid. The CSF sodium level may be based on the sodium concentration in the saliva. | 10-25-2012 |
| 20120270817 | 6-Substituted Estradiol Derivatives and Methods of Use - A method of inhibiting growth of cancer cells comprising contacting cancer cells with a 6-substituted estradiol derivative in an amount at least partially sufficient to inhibit said growth is disclosed. The compounds have the general formula depicted below, wherein R | 10-25-2012 |
| 20120283202 | ANTI-WART PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING WART - Disclosed herein is an anti-wart pharmaceutical composition including a water-soluble extract from a plant of | 11-08-2012 |
| 20120289473 | TREATMENT AND/OR PREVENTION OF INFLAMMATION AND CUTANEOUS PHOTODAMAGE AND PHOTOPROTECTION OF THE SKIN WITH A WATER-SOLUBLE EXTRACT FROM PLANT OF SOLANUM GENUS - The present invention relates to a pharmaceutical composition for preventing and treating inflammation and cutaneous photodamage, which contains a water-soluble extract from a plant of | 11-15-2012 |
| 20120289474 | 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4,3-c] ISOQUINOLINE DERIVATIVES - The compounds of Formula (1), | 11-15-2012 |
| 20120295857 | EXTRACT OBTAINED BY A COMMERCIALLY VIABLE PROCESS FOR THE EXTRACTION OF FUROSTANOLIC SAPONINS FROM FENUGREEK SEEDS, IN WHICH ONE OF THE COMPOUNDS IN THE EXTRACT IS PROTODIOSCIN - Disclosed is an extract obtained by a commercially viable process for the extraction of furostanolic saponins from fenugreek seeds, in which one of the compounds in the extract is protodioscin. The process includes providing plurality of fenugreek seeds and crushing the same by milling and grinding; performing a primary extraction on the prepared fenugreek seeds using a first hydrophilic polar solvent which is a lower primary aliphatic alcohol followed by ion-exchange chromatography; performing a secondary extraction after ion-exchange chromatography using a composite solvent; and decolorizing the final extract by use of activated charcoal concentration of the extract by heating and vacuum drying sieving the final powdered product. | 11-22-2012 |
| 20120295858 | USE OF DANSHENSU, NOTOGINSENOSIDE R1 OR THEIR COMBINATION IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING DISEASES CAUSED BY MICROCIRCULATION DISORDER - The present invention relates to a new use of traditional Chinese drug products of Danshensu (DLA), Notoginsenoside R1 (R1) and their combination, in particular to the therapeutic and preventive effects of DLA, R1 and their combination on the diseases caused by microcirculation disorder. | 11-22-2012 |
| 20120309700 | DEVELOPMENT AND EVALUATION OF NOVEL CHINESE MATERIA MEDICA PREPARATIONS - Nuclear receptor LXR is an important member of 49 nuclear receptors in human bodies and has irreplaceable regulatory effects on cholesterol and fat metabolisms. The regulation of the biological activity of LXR may have therapeutic effects to the conditions such as cardiovascular and cerebrovascular obstructions, non-insulin dependent hyperglycemia, immune function disorders, and central nerve functional degeneration. We have developed a group of novel Chinese materia medica preparations targeting nuclear receptor LXR by using a computer-simulated docking technology and a process for determining biological activities of human cells cultured ex vivo. The group of preparations are featured by simple ingredients, low costs, easy to prepare, etc. No significant adverse effects were found in initial acute toxicology analysis which was carried out using mice. | 12-06-2012 |
| 20120316122 | PHARMACEUTICAL COMPOSITIONS FOR COMBATING THROMBOTIC DISEASES AND THEIR PREPARATION AND USES - The present invention relates to a pharmaceutical composition for combating a thrombotic disease and a method for making the same and a use thereof. The pharmaceutical composition mainly comprises timosaponin AIII and timosaponin BII, and optionally pharmaceutically acceptable excipients, characterized in that the amount of timosaponin AIII is greater than or equal to the amount of timosaponin BII. The present invention further relates to a use of timosaponin AIII and timosaponin BII in manufacturing a medicament or product for the prophylaxis or to treatment of a thrombotic disease. The present pharmaceutical composition can not only bring about effects of prophylaxis or treatment of a thrombotic disease, but also alleviate blood bleeding or bleeding tendency in patients. | 12-13-2012 |
| 20120322752 | SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL - The present invention provides solid dispersion, comprising: 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol which is a pharmacologically active ingredient; and a saturated polyglycolized glyceride which is a lipid matrix. The solid dispersion of the present invention has effects of increasing dissolution rate of 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol. | 12-20-2012 |
| 20120322753 | PRODUCTION METHOD OF SOLID PREPARATION AND THE SOLID PREPARATIONS PRODUCED BY THE METHOD - The production method prepares a solid preparation by dissolving water-insoluble and/or water indissolvable alkaline active pharmaceutical ingredient in an acidifier-containing acid solution to obtain medicated acid liquid; homogeneously mixing alkalizer, adjuvants and the medicated acid liquid, and carrying out wet granulation. The alkalizer is a reagent to reduce the acidity of the mixture of the alkalizer and the medicated acid liquid relative to the acidity of the medicated acid liquid. The preparation method avoids the problems in mechanical pulverization, such as environmental pollution, great loss and serious security risks. This method is simply operated, has high safety coefficient and is convenient for industrialized production. Also disclosed is the solid preparation produced by the method. The solid preparation produced by the method has better dissolution performance than that produced by prior art, and has better or at least equivalent stability and content uniformity with prior art. | 12-20-2012 |
| 20120329738 | Water Soluble Drug-Solubilizer Powders and Their Uses - Enhanced methods have been discovered, using either sonication or homogenization followed by increased temperature and pressure, to solubilize compounds using diterpene glycosides and to produce a powder form of the compound-solubilizer complex than can be reconstituted in water. Without the diterpene glycoside, the compounds were insoluble or sparingly soluble in water, including some fat-insoluble vitamins. Water solutions of these compounds were made using a diterpene glycoside solubilizer, for example, rubusoside. The compound-solubilizer complex was then dehydrated to a stable powder that could then be reconstituted with water. A reconstituted drug-solubilizer complex (curcumin-rubusoside) was shown to be effective on reconstitution. In addition, the diterpene glycoside, rubusoside, was shown to be an inhibitor of permeability glycoprotein (P-gp), and will thus increase gastrointestinal absorption of certain drugs administered with rubusoside. | 12-27-2012 |
| 20130012462 | RECEPTOR MODULATORS EXHIBITING NEUROPROTECTIVE AND MEMORY ENHANCING ACTIVITIES - The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in preventing and treating central nervous system disorders by inhibiting over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of treating and/or preventing neurodegenerative diseases and neuropathological disorders, methods of providing neuroprotection under stress conditions such as a stroke, methods of enhancing the brain's cognitive functions and methods of treating depression, anxiety and cachexia induced by a chronic disease in mammals and humans. | 01-10-2013 |
| 20130023487 | COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION - Compounds from 14 Kenyan plants, including from the root of | 01-24-2013 |
| 20130023488 | METHODS AND COMPOUNDS FOR REDUCING INTRACELLULAR LIPID STORAGE - Compounds and compositions for reducing intracellular lipid accumulation in a cell are described herein. These compounds are useful for the treatment and prevention of lipid/glycogen disorders, as well as for the treatment and prevention of obesity. A high throughput screen for identifying compounds that reduce intracellular lipid accumulation in cells is also provided. | 01-24-2013 |
| 20130040903 | PHARMACEUTICAL COMPOSITIONS FOR TREATING DEPRESSION AND ANXIETY - Pharmaceutical compositions or functional foods for treating depression and anxiety comprising ginseng saponin (Rgl+Rbl), glycyrrhizic acid and jujuba cAMP. Experiments demonstrate that as compared with the preferred drug for treating depression and anxiety paroxetine and diazepam in the art, the present invention has significant anti-depression and anxielytic efficacy. | 02-14-2013 |
| 20130059804 | SYNTHESIS OF COMPOUNDS USEFUL AS MODULATORS OF AMYLOID-BETA PRODUCTION - As described herein, the present invention provides methods for preparing compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease. | 03-07-2013 |
| 20130065842 | COMPOUNDS AS RORyT MODULATORS AND USES THEREOF - Heterocyclic compounds, and pharmaceutical compositions thereof, are disclosed as RORγt modulators that have a formula represented by the following: | 03-14-2013 |
| 20130072451 | Low Viscosity Personal Care Composition - A low viscosity personal care composition comprising from about 10 % to about 99% of water, from about 0.01% to about 20% of a suspended particulate material, from about 0.01% to about 5% of an acrylic polymer, wherein the composition has a viscosity of from about 80 to about 1000 mPa·s, and a pH of from about 4 to about 9, wherein the acrylic polymer provide a selection yield value of at least 0.11 Pa. An array of two or more low viscosity personal care compositions, wherein one of the personal care compositions comprises said particulate material at a level different from those in the other personal care compositions. | 03-21-2013 |
| 20130079293 | NEURO-PROTECTIVE EFFECTS OF ADELOSTEMMA GRACILLIMUM AND ITS ISOLATED COMPOUNDS - Isolated compounds from | 03-28-2013 |
| 20130102549 | VEGF Production Promoter - Provided are a VEGF production promoter, a hair quality improver, and an external preparation for skin, each of which has a VEGF production promoting activity and can be used as a pharmaceutical agent, a cosmetic, a food, or a material therefor. | 04-25-2013 |
| 20130109638 | ANTI-ACNE PHARMACEUTICAL COMPOSITION | 05-02-2013 |
| 20130109639 | NEPRILYSIN INHIBITORS | 05-02-2013 |
| 20130178430 | Compositions for Prevention or Treatment of Hepatitis C Virus Containing ginsenoside Rg3 as an Active Ingredient - This invention is for the compound containing ginsenoside Rg3 as an active ingredient to prevent and treat Hepatitis C virus infection. Specifically, the ginsenoside Rg3 of this invention demonstrated the predominant antiviral activities and apotosis actions in a dose-dependent manner in the Hepatitis C virus infected cells (Huh 7.5.1). Confirmed that it reduces the levels of TNF-α and thioredoxin significantly, and increases phospho-NFκB. It also demonstrated same effectiveness as PegInterferone alpha-2b(PegIFN a-2b, Hepatitis C therapeutics), and has no cytotoxicity to human bodies. Thus, it may be used safely as an active ingredient of medical/pharmaceutical and health food compounds for preventing or treating Hepatitis C. | 07-11-2013 |
| 20130178431 | GLYCOSIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention provides glycoside compounds, methods of preparing such compounds, pharmaceutical compositions comprising such compounds, and a method for the treatment of hyperproliferative diseases using the same. | 07-11-2013 |
| 20130203690 | PDE III INHIBITORS FOR TREATMENT OF ASYMPTOMATIC HEART FAILURE - Phosphodiesterase type III (PDE III) inhibitor or a “Ca | 08-08-2013 |
| 20130210752 | USING A NOVEL HIGH-THROUGHPUT YEAST CELL-BASED SCREENING PLATFORM TO IDENTIFY HMG-COA REDUCTASE INHIBITORS FROM NATURAL PRODUCTS AND THE USES OF SUCH INHIBITORS THEREOF - Methods of screening, identifying and isolating HMG-CoAR inhibitors are disclosed herein. In particular, said method is useful for screening natural raw products. The present invention also provides potent HMG-CoAR inhibitors for treatment and prevention of diseases and conditions associated with elevated cholesterol and/or blood lipid levels. | 08-15-2013 |
| 20130225515 | METHOD FOR ISOLATING SMALL MOLECULES WITH IMPORTANT BIOLOGICAL ACTIVITY USING YEAST - Methods of isolating biologically active molecules from an organism, for example from a fungus, are described. The methods involve isolating an active molecule which possesses a specific biological activity on, in or against wild-type yeast cells, but not on, in or against yeast cells that express a given ABC transporter from a given organism, including but not limited to | 08-29-2013 |
| 20130244960 | Treatment for Alzheimer's Disease - Using a Pharmaceutically Suitable Preparation containing one more Cardio Glycosides such as THEVETIN B, THEVETIN A, PERUVOSIDE, THEVOFOLIN, OLEANDRIN, NERIIFOLIN, THEVETOXIN Derived and or Extracted from the Yellow Oleandrin Plant ( | 09-19-2013 |
| 20130267475 | Method of Treating Neurological Conditions with Oleandrin - A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside to a subject. The cardiac glycoside can be present in a dosage form. | 10-10-2013 |
| 20130281387 | Chemosensory Receptor Ligand-Based Therapies - Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention. | 10-24-2013 |
| 20130303470 | PLANT EXTRACTION METHOD AND COMPOSITIONS - The present invention pertains to methods of extracting cardiac glycosides from cardiac glycoside containing plant material, such as | 11-14-2013 |
| 20130324485 | Method of Determining the Probability of a Therapeutic Response in Cancer Chemotherapy with Cardiac Glycoside - A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the α subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside. | 12-05-2013 |
| 20130324486 | METHOD FOR PRODUCING CULTURED ROOT OF PURPLE GINSENG - The present invention relates to a novel method for processing a cultured root of purple wild ginseng for increasing saponin content and to the cultured root of the purple wild ginseng which is processed thereby. The present invention can provide the cultured root of wild ginseng having significantly higher content of a specific ginsenoside, and can increase the productivity and economic efficiency by simplifying the production process. | 12-05-2013 |
| 20130345156 | AQUEOUS SOLUTION OF 20(R)-GINSENOSIDE RG3 PHARMACEUTICAL COMPOSITION AND PROCESS THEREOF - A preparation of a kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution containing ginsenoside Rg3 0.5˜10 mg/ml: add 0.1-5% of ginsenoside solution to 0.1˜30% of adjuvant A, B{circle around (1)}{circle around (2)}{circle around (5)} at the temperature of 40˜100° C., the ratio of these two is 1:1˜300, add water after the solvent is recycled under reduced pressure; another kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution contains 0.1˜2 mg/ml of 20 (R) of the ginsenoside Rg3, the preparation: add 0.1˜5% of ginsenoside solution to 20˜65% of adjuvant B{circle around (3)}{circle around (4)} at the temperature of 60˜100° C., main material to adjuvant B=1:100˜400, add water after the solvent is recycled under reduced pressure. The above 20 (R) ginsenoside Rg3 composition aqueous solution and the powder after lyophilizaton can be used to prepare injectable, oral administration and external use, and the bioactivity of these preparations is high, and with the actions of anti cancer, efficacy potentiation and toxicity attenuation effects of the combined chemical or radiation therapy of tumor, enhancement of human immune functions, improvement of human memory, anti fatigue, and detumescence, pain relieving. | 12-26-2013 |
| 20140005132 | CONTRACEPTIVE AGENTS | 01-02-2014 |
| 20140051652 | Treatment for Migraine Headache - Using a Pharmaceutically Suitable Preparation containing one more Cardio Glycosides such as THEVETIN B, THEVETIN A, PERUVOSIDE, THEVOFOLIN, OLEANDRIN, NERIIFOLIN, THEVETOXIN Derived or Extracted from the Yellow Oleandrin Plant (Oleandrin Peruviana), White Oleandrin Plant (Nerium Oleander) and or other Plants in the Apocynaceae Genus, in the Dogbane Plant Family and or extracted from plants or animals including plants and animals such as Foxglove or synthetic man-made, and or a combination of synthetic and natural thereof in Pharmaceutically Suitable Preparation in a Pharmaceutically Suitable Dose, example orally or intravenously, of which the Prescriber of the said Preparation, or Doctor, based on the overall health of the Patient will prescribe the best Dosage, The Best Mode of Dosage example orally or intravenously, which is best suited to have the Most Desirable Therapeutic Effect | 02-20-2014 |
| 20140066391 | STEROID COMPOUNDS AS RORyt MODULATORS AND USES THEREOF - Steroid compounds are disclosed that have a formula represented by the following: | 03-06-2014 |
| 20140066392 | COMBINATION TREATMENTS FOR MELANOMA - The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include BRAF inhibitors such as PLX 4720 and PLX 4734 in combination with RO 31-8220, bafetinib or cardiac glycosides. | 03-06-2014 |
| 20140073590 | Methods for Treating Pulmonary Hypertension - The present invention relates to methods for treating or preventing pulmonary hypertension, reducing mortality in a subject experiencing pulmonary hypertension, or inhibiting ADP-mediated vasoconstriction of pulmonary arteries in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a reversible P2Y | 03-13-2014 |
| 20140080772 | TREATMENTS FOR MELANOMA - The present invention relates to mono- and combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include RO 31-8220, bafetinib, and cardiac glycosides. | 03-20-2014 |
| 20140135278 | Novel Ginsenoside With Anti-cancer Activity And The Preparation Method Thereof - The present invention relates to a novel compound derived from ginsenoside Rh2, the preparation methods and the use thereof in treating cancers. | 05-15-2014 |
| 20140135279 | OSW-1 ANALOGS AND CONJUGATES, AND USES THEREOF - Provided are a number of compounds structurally related to OSW-1, a natural compound that binds OSBPs. Also provided are pharmaceutical compositions comprising the OSW-1 analogs, as well as methods for use of these OSW-1 analogs, or pharmaceutically acceptable salts, enantiomers, or stereoisomers thereof in the treatment of atherosclerosis. Alzheimer's disease, and cancer, including p21-deficient cancer. Conjugates of OSW-1 analogs with monoclonal antibodies, including monoclonal antibodies targeted to cancer cells, are also provided. Also provided are pharmaceutical compositions comprising the conjugates, as well as methods for use of these conjugates, in the treatment of cancer, including p21-deficient cancer. | 05-15-2014 |
| 20140155337 | Molluscicidal Agents and Uses Thereof - The present invention provides molluscicidal saponins and saponin fractions from | 06-05-2014 |
| 20140155338 | USE OF PDE III INHIBITORS FOR THE REDUCTION OF HEART SIZE IN MAMMALS SUFFERING FROM HEART FAILURE - A phosphodiesterase type III (PDE III) inhibitor or Ca | 06-05-2014 |
| 20140162966 | NANOPARTICLES FOR DELIVERY OF LIGANDS - Disclosed is a nanoparticulate complex comprising an artificial phosphate receptor of formula (I): P-[L-[-N(CH | 06-12-2014 |
| 20140187505 | Cardiac Glycosides to Treat Cystic Fibrosis and Other IL-8 Dependent Disorders - Disclosed is the use of a cardiac glycoside to decrease or inhibit the secretion of proinflammatory mediators in the treatment of disease conditions characterized by elevated levels of the proinflammatory mediator. The cardiac glycoside is administered to a mammalian subject in need of such treatment, and dosage is adjusted to the mass of the recipient and the need of the recipient to reduce or inhibit the level of the proinflammatory mediator. The proinflammatory mediators suppressed by the invention include IL-8, IL-6, TNFalpha, ICAM-1, IFNgamma, IL-1-beta, MCP-1, MIP-2, and/or epithelial-mesenchymal-transition (EMT). The cardiac glycoside, digitoxin or oleandrin, can be formulated for administration by injection or as an aerosol administered to the respiratory tract or by being ingested, or as nose drops or nasal spray. According to one use, the digitoxin controls microRNA expression in castration-resistant prostate cancer. The microRNA suppresses IL-8 and IL-6 expression in these cells. | 07-03-2014 |
| 20140206631 | Cardiac Glycoside Analogs in Combination with Emodin for Cancer Therapy - A method and medicine for treating leukemia or other cancer includes administering to a patient diagnosed with leukemia or other cancer a treatment regimen that includes periodic doses of a combination of emodin and digoxin. | 07-24-2014 |
| 20140206632 | Endothelin in the Diagnosis of Cardiac Disease - A method for determining the risk, severity or progression of cardiovascular disease, such as cardiac heart failure. A method for determining the likelihood of admission to the hospital for cardiac heart failure. The methods include determining the concentration of ET-1 and the concentration of one or more of biomarkers selected from the group consisting of cardiac troponin (e.g., cTnI, cTnT), VEGF, BNP, NT-proBNP, and IL-6 in a blood, serum or plasma sample from the patient. | 07-24-2014 |
| 20140256660 | ANTIBIOTIC CONJUGATES LINKED WITH STEROID DRUGS - The present invention describes novel single drug entities, formed by the linkage of an antibiotic with a steroidal drug via a linker. Upon topical application to the eye, the conjugate would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs. | 09-11-2014 |
| 20140274923 | MIRNAS AS A PROGNOSTIC BIOMARKER IN PEDIATRIC HEART FAILURE - The present invention provides for methods of predicting progression of pediatric heart failure using miRNA biomarkers, as well as subsequent treatment of patients based on their classification. | 09-18-2014 |
| 20140288015 | METHODS AND DEVICES FOR AFFECTING NERVE FUNCTION - Various methods and devices are described for affecting nerve function in the carotid body, renal nerves, and other nerves. Syringes, endovascular catheters, drug-eluting balloons, drug-eluting stents, and agent delivery patches are used to deliver a neuromodulatory agent to one or more nerves in order to treat a disease state. | 09-25-2014 |
| 20140296170 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF BONE DISEASES COMPRISING SPINASTEROL GLUCOSIDE DERIVATIVE - Disclosed is a pharmaceutical composition for the prevention or treatment of metabolic bone diseases, comprising a spinasterol glucoside derivative, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof. The pharmaceutical composition is effectively useful for preventing or treating metabolic bone diseases. | 10-02-2014 |
| 20140336138 | COMPOSITIONS AND METHODS FOR SCREENING AND TREATMENT OF STURGE-WEBER SYNDROME, KLIPPEL-TRENAUNAY-WEBER SYNDROME, AND PORT-WINE STAINS (PWSS) - Compositions and methods for treatment of Sturge-Weber Syndrome, Klippel-Trenaunay-Weber Syndrome, Port-Wine Stains and related neurocutaneous disorders are provided. Cell lines having the somatic mutation GNAQ p.Arg183Gln amino acid substitution, which was found to be the cause of port-wine stains (prevalence 1 in 300) and Sturge-Weber syndrome are also provided. Compositions and methods for treatment of uveal melanoma are also provided herein. Methods of screening novel compounds and compositions useful in increasing RGS2 and/or RGS4 expression and function in vitro, and for treatment of Sturge-Weber Syndrome, Klippel-Trenaunay-Weber Syndrome, Port-Wine Stains and related neurocutaneous disorders are provided are also provided. | 11-13-2014 |
| 20140378399 | NOVEL VASCULAR LEAKAGEAGE INHIBITOR - The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present invention inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, and enhances the cortical actin ring structure, thereby inhibiting vascular leakage. Accordingly, the vascular leakage inhibitor of the present invention can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present invention is synthesized from commercially available or easily synthesizable pregnenolones, it has remarkably superior feasibility of commercial synthesis. | 12-25-2014 |
| 20150065440 | SULFATED OLIGOSACCHARIDE DERIVATIVES - The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject. | 03-05-2015 |
| 20150080327 | Targeted Osmotic Lysis of Cancer Cells - A targeted osmotic lysis (TOL) of tumor cells that over-express voltage-gated sodium channels (VGSCs) has been developed that uses a combined therapy of a drug that blocks sodium, potassium-adenosine triphosphatase (Na | 03-19-2015 |
| 20150099711 | METHOD AND SYSTEM FOR MODIFYING RAW FOODS, AND RAW FOOD PRODUCT MADE THEREBY - A method for modifying a quality of a fruit includes cutting a live stem attached to a live fruit at a cut distance from the fruit, producing a cut end of the stem, contacting only the cut end of the stem with a solution comprising at least one mobile and quality-modifying food ingredient while protecting the fruit from contact with the solution, and keeping the cut end of the stem in contact with the solution for an incubation time sufficient to allow absorption and transport of the food ingredient into the fruit, the food ingredient conferring a modified quality upon the fruit. A system for practicing the method and an edible raw plant product produced by the method are also disclosed. | 04-09-2015 |
| 20150099712 | METHOD AND COMPOUNDS FOR INHIBITING THE MCM COMPLEX AND THEIR APPLICATION IN CANCER TREATMENT - A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM subunits, such as hMcm2 and hMcm6, in cells treated with candidate compounds. | 04-09-2015 |
| 20150111843 | DERIVATIVES OF AVICIN D AND METHODS OF MAKING AND USING THEREOF - Disclosed herein are novel oxetane derivatives of avicin D, including compounds of the formula (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising these derivative compounds. Methods and intermediates useful for making the derivatives, and methods of using the derivatives and compositions thereof, including for the treatment of cancer, are also provided. | 04-23-2015 |
| 20150126463 | USE OF HERBAL SAPONINS TO REGULATE GUT MICROFLORA - The present invention relates to the use of a compound comprising plant based saponins for regulating and balancing gut microflora in a subject. The present invention also relates to the use of a compound comprising plant based saponins for exerting anti-cancer effects by regulating and balancing the gut microbial ecosystem for a subject. | 05-07-2015 |
| 20150126464 | THERAPEUTIC DRUG AND THERAPEUTIC METHOD FOR NEUROLOGICAL DISEASES INCLUDING ALZHEIMER'S DISEASE ASSOCIATED WITH 1,25D3-MARRS - A primary objective is to provide a drug for radical cure and a therapeutic method for diseases associated with axonal dysfunction (for example, Alzheimer's disease, dementia, Parkinson's disease, spinal cord injury, or brain contusion) based on the pathogenic mechanism thereof. | 05-07-2015 |
| 20150297727 | SAPONIN NANO MICELLE, PREPARING METHOD, APPLICATION AND PHARMACEUTICAL COMPOSITION THEREOF - A saponin nano micelle, preparing method, application and pharmaceutical composition thereof is disclosed in the present invention. The saponin nano micelle comprises one or more of saponins represented by formula 1, in which, R | 10-22-2015 |
| 20150306119 | APPLICATION OF AMERICAN GINSENG TO ENHANCE NEUROCOGNITIVE FUNCTION - Disclosed are methods of enhancing neurocognitive function by administering of American | 10-29-2015 |
| 20150313926 | SYN3 COMPOSITIONS AND METHODS - Disclosed are aqueous and nonaqueous solution formulations containing agents that are useful for treating cancer. | 11-05-2015 |
| 20150328121 | Skin-Moisturising or Wrinkle-Improving External Composition and Cosmetic Composition - The present invention relates to a skin-moisturizing or wrinkle-improving external composition or cosmetic composition which contains, as an active ingredient, a compound represented by Formula 1, which can be extracted from | 11-19-2015 |
| 20160000963 | FORMATION OF SEMI-PERMEABLE POROUS ARTIFICAL SCAB - Pourous semi-ermeable artificial self-attaching scab designed to protect the eroded or injured surfaces. | 01-07-2016 |
| 20160008385 | ADRENOMEDULLIN PRODUCTION ENHANCER | 01-14-2016 |
| 20160047822 | BIOMARKER FOR DIAGNOSIS, PREDICTION AND/OR PROGNOSIS OF ACUTE HEART FAILURE AND USES THEREOF - The application discloses MCAM as a new biomarker for acute heart failure; methods for predicting, diagnosing, prognosticating and/or monitoring acute heart failure based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 02-18-2016 |
| 20160067270 | USE OF GINSENOSIDE F2 FOR PROPHYLAXIS AND TREATMENT OF LIVER DISEASE - Provided are use of ginsenoside F2 in the prevention, improvement or treatment of liver disease, and a pharmaceutical composition, a health functional food, and a feed composition including ginsenoside F2. Ginsenoside F2 inhibits fat synthesis and accumulation in the liver, and increases distribution of regulatory T cells capable of inhibiting activity of inflammatory cells, thereby preventing hepatitis, and also increases expression of anti-inflammatory cytokine IL-10 in regulatory T cells, and inhibits differentiation of naive T cells into Th17 cells, and is thereby effectively used for the treatment of various liver diseases. | 03-10-2016 |
| 20160143934 | CARDIAC GLYCOSIDE ANALOGS AND THEIR USE IN METHODS FOR INHIBITION OF VIRAL INFECTION - The present invention provides methods for inhibition of human herpes virus replication in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutically acceptable composition comprising a cardiac glycoside analog, including for example, a digitoxin analog and pharmaceutically acceptable carrier. Other methods of the present invention include administering a digitoxin analog along with at least one other biologically active compound and pharmaceutically acceptable carrier. Methods for inhibition of the α3 subtype of the Na/K ATPase in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutically acceptable composition comprising a digitoxin analog are also provided. | 05-26-2016 |
| 20160143936 | Treatment for Migraine - The present invention relates to methods for the treatment of migraine headache, cluster headache, tension type headache, trigeminal neuralgia (trigeminal headache) and headache disorders. The methods comprise administration of specific cardiac glycosides: Thevetin A and or Thevetin B to a subject in need thereof a pharmaceutically suitable preparation, in the form of nasal spray and or other modes and methods that will ensure adequate intranasal dosage, a pharmaceutically suitable preparation of the said cardiac glycosides that is sufficient to have the most desirable therapeutic effect when used as a prophylaxis, as a treatment and ameliorating agent of migraine headache and others headache disorders. | 05-26-2016 |
| 20160150789 | PROCESS TO OBTAIN AN EXTRACT FROM SOLANUM GENUS PLANTS | 06-02-2016 |
| 20160151387 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | 06-02-2016 |
| 20160176914 | GLYCOSYLATED CARDIOTONIC STEROIDS | 06-23-2016 |
| 20160184207 | HAIR GROWTH AND HAIR RESTORATION MATERIAL - Provided is a novel hair growth and hair restoration material having excellent efficacy in hair growth and hair restoration for both men and women, even when the components thereof are at ultra-dilute concentrations; the hair growth and hair restoration material being characterized in containing a sterol glucopyranoside, preferably a cholesteryl glucopyranoside, represented by general formula (I). (In the formula, Z represents a sterol residue from which the hydroxyl group attached to the 3-position of a cyclopentanohydrophenanthrene ring has been removed.) | 06-30-2016 |
| 20160184249 | TRADITIONAL CHINESE MEDICINE COMPOSITION - A traditional Chinese medicine composition and preparation thereof for treating cardiovascular diseases is provided. The traditional Chinese medicine composition consists of: by weight percentage, phenolic acid derivatives 30%˜80%, tanshinones 2%˜10% and saponins 15%˜60%. | 06-30-2016 |
| 20160250240 | METHODS AND COMPOSITIONS FOR PROMOTING ACTIVITY OF ANTI-CANCER THERAPIES | 09-01-2016 |
| 20170232027 | NOVEL COMPOSITIONS AND METHODS USEFUL FOR TREATING OR PREVENTING LIVER DISEASES OR DISORDERS, AND PROMOTING WEIGHT LOSS | 08-17-2017 |
